Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr DeAngelo on Challenges With Utilizing Pediatric-Inspired Regimens in Adult and AYA ALL

June 19th 2025

Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyper‐CVAD in adult and AYA patients with ALL.

Conversations About BTK Inhibitors and CAR T-Cell Therapies Bridge Gaps in Leukemia and Lymphoma: With Alexey Danilov, MD, PhD

June 19th 2025

Dr Danilov highlights advances and questions in the management of mantle cell lymphoma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma.

Updated Data From Phase 1 Trials Support Shifts in the Lung Cancer Treatment Paradigm

June 19th 2025

Martin E. Gutierrez, MD, discusses steps towards a continuous shift in both the NSCLC and SCLC treatment paradigms, based on trials presented at ASCO 2025.

Dr Chung on the Potential Role for Ficerafusp Alfa Plus Pembrolizumab in the HPV-Negative HNSCC Paradigm

June 18th 2025

Christine Chung, MD, contextualizes efficacy data with ficerafusp alfa plus pembrolizumab within the larger treatment paradigm for HPV-negative HNSCC.

Dr Landgren on the Efficacy of Dara-KRd in Newly Diagnosed Myeloma Regardless of Transplant Eligibility

June 18th 2025

C. Ola Landgren, MD, PhD, discussed the benefit of Dara-KRd in patients with multiple myeloma stratified by transplant eligibility, risk, and age.

Dr Komrokji on the Effect of Prior Treatment on Imetelstat Activity in Transfusion-Dependent LR-MDS

June 18th 2025

Rami Komrokji, MD, shares results from a pooled analysis of outcomes with imetelstat based on prior therapy in transfusion-dependent lower-risk MDS.

Long-Term Data Support Venetoclax Plus Rituximab in Relapsed/Refractory CLL

June 18th 2025

Venetoclax plus rituximab displayed OS and PFS benefits vs BR after long-term follow-up in relapsed/refractory CLL.

Dr Lin on the Rationale for Evaluating Cilta-Cel–Associated Late-Onset Toxicities in Myeloma

June 18th 2025

Yi Lin, MD, PhD, discusses the rationale for evaluating the onset of delayed toxicities following cilta-cel infusion in patients with multiple myeloma.

Real-World Analysis Suggests Social Determinants of Health May Be Associated With Early Onset of CRC

June 18th 2025

Jessica Paulus, ScD, highlights factors that may contribute to the increasing incidence of colorectal cancer in patients younger than 50 years of age.

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

June 17th 2025

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Paulus on Factors Contributing to Earlier Onset of CRC in Younger Patients

June 17th 2025

Jessica Paulus, ScD, discusses findings from a real-world, retrospective analysis of factors contributing to early-onset CRC.

Dr Duska on the Adoption of Pembrolizumab Plus Concurrent CRT as a SOC in Advanced Cervical Cancer

June 17th 2025

Linda R. Duska, MD, MPH, discusses the need for continued research with concurrent chemoradiation in high-risk advanced cervical cancer.

Dr Tan on Important Considerations for Nivolumab/Ipilimumab Selection in Metastatic ccRCC

June 17th 2025

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

Health Canada Approves Quizartinib Plus Chemotherapy for Newly Diagnosed FLT3-ITD+ AML

June 17th 2025

Health Canada has approved a quizartinib-based regimen for the treatment of patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

VERONA Trial Misses Primary End Point of OS Benefit With Azacitidine/Venetoclax in Higher-Risk MDS

June 17th 2025

Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.

Retifanlimab Presents a New Treatment Option for Locally Recurrent or Metastatic SCAC

June 17th 2025

Cathy Eng, MD, FACP, FASCO, highlights the significance of the FDA approval of retifanlimab for managing locally recurrent or metastatic SCAC.

Dr D'Amato on the Implications of Data With Olaparib Plus Temozolomide in Advanced Uterine Leomyosarcoma

June 16th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Dr Munir on the Efficacy of First-Line Zanubrutinib vs Acalabrutinib Plus Venetoclax in CLL

June 16th 2025

Tahla Munir, MBChB, PhD, details the efficacy of first-line zanubrutinib and clinical implications for treatment selection in CLL.

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

June 16th 2025

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

Dr Chehrazi-Raffle on the Safety of Second-Line Tivozanib With/Without Nivolumab in RCC

June 13th 2025

Alexander Chehrazi-Raffle, MD, details safety data and the clinical implications of an analysis of second-line tivozanib for patients with metastatic RCC.